Scholar Rock Holding Co. (NASDAQ:SRRK) Receives $40.43 Average PT from Analysts

Shares of Scholar Rock Holding Co. (NASDAQ:SRRKGet Free Report) have been given a consensus rating of “Buy” by the seven brokerages that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $40.86.

A number of equities analysts have recently weighed in on the company. HC Wainwright upped their target price on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Truist Financial upped their target price on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Finally, Wedbush restated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Monday.

Check Out Our Latest Stock Analysis on Scholar Rock

Insider Buying and Selling

In other Scholar Rock news, CFO Edward H. Myles sold 12,539 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $554,223.80. Following the completion of the sale, the chief financial officer now owns 148,549 shares of the company’s stock, valued at $6,565,865.80. This represents a 7.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jing L. Marantz sold 5,655 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $249,951.00. Following the sale, the insider now directly owns 67,200 shares of the company’s stock, valued at $2,970,240. The trade was a 7.76 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 292,266 shares of company stock worth $10,996,151. Insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

A number of large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in shares of Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after acquiring an additional 269 shares during the period. Quarry LP boosted its position in shares of Scholar Rock by 3,443.3% in the third quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after acquiring an additional 4,373 shares during the period. Global Retirement Partners LLC boosted its position in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after acquiring an additional 766 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after acquiring an additional 1,031 shares during the period. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Scholar Rock in the fourth quarter valued at approximately $85,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

Shares of SRRK opened at $34.72 on Thursday. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of -14.77 and a beta of 0.59. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The business’s 50-day moving average is $39.30 and its 200-day moving average is $31.68.

Scholar Rock Company Profile

(Get Free Report

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Further Reading

Analyst Recommendations for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.